# Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

> **NCT00121849** · PHASE1 · COMPLETED · sponsor: **Access to Advanced Health Institute (AAHI)** · enrollment: 12 (—)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **BIOLOGICAL:** Leish-111f + MPL-SE vaccine

## Key facts

- **NCT ID:** NCT00121849
- **Lead sponsor:** Access to Advanced Health Institute (AAHI)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 12 (—)
- **Last updated:** 2006-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121849, "Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00121849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*